Collaboration Tests TRX518-Bavencio Combo in Phase 1/2 Trial of Solid Tumors
News
Leap Therapeutics is launching a Phase 1/2 clinical trial to test its immunotherapy TRX518 in combination with Bavencio (avelumab) and chemotherapy in advanced solid tumors, as part of a collaboration established with Merck KGaA and Pfizer — the two ... Read more